BioCorRx, Inc. engages in the provision of alcoholism and opioid addiction treatment. It offers treatment philosophy that combines medical intervention and a proprietary cognitive behavioral therapy program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. It also engages in the research and development of sustained release naltrexone products for the treatment of addiction and other possible disorders. The company was founded by Neil Terrence Muller and George O'Neill on January 28, 2008 and is headquartered in Anaheim, CA.
Company profile
Ticker
BICX
Exchange
Website
CEO
Brady Granier
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Cetrone Energy CO, FRESH START PRIVATE MANAGEMENT, INC.
SEC CIK
Corporate docs
IRS number
261972677
BICX stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
3 Apr 24
10-K
2023 FY
Annual report
1 Apr 24
8-K
Departure of Directors or Certain Officers
5 Jan 24
8-K
Entry into a Material Definitive Agreement
14 Dec 23
8-K
Entry into a Material Definitive Agreement
16 Nov 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
8-K
Departure of Directors or Certain Officers
2 Nov 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
10-Q
2023 Q1
Quarterly report
15 May 23
8-K
Entry into a Material Definitive Agreement
11 Apr 23
Transcripts
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 156.41 k | 156.41 k | 156.41 k | 156.41 k | 156.41 k | 156.41 k |
Cash burn (monthly) | 13.63 k | (no burn) | 320.62 k | 345.91 k | 116.85 k | 147.42 k |
Cash used (since last report) | 93.81 k | n/a | 2.21 mm | 2.38 mm | 804.12 k | 1.01 mm |
Cash remaining | 62.60 k | n/a | -2.05 mm | -2.22 mm | -647.71 k | -858.08 k |
Runway (months of cash) | 4.6 | n/a | -6.4 | -6.4 | -5.5 | -5.8 |
Institutional ownership, Q4 2020
0.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 47.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
IFP Advisors | 47.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
28 Mar 24 | Felix Lourdes | Common Stock, par value $0.001 | Grant | Acquire A | No | No | 0 | 5,566 | 0.00 | 80,395 |
28 Mar 24 | Lucido Louis C. | Common Stock, par value $0.001 | Grant | Acquire A | No | No | 0 | 18,553 | 0.00 | 534,213 |
28 Mar 24 | Lucido Louis C. | Common Stock, par value $0.001 | Grant | Acquire A | No | No | 0 | 5,566 | 0.00 | 515,660 |
28 Mar 24 | Granier Brady James | Stock Option Common Stock | Grant | Acquire A | No | No | 0.9 | 16,698 | 15.03 k | 16,698 |
29 Feb 24 | Lucido Louis C. | Common Stock, par value $0.001 | Grant | Acquire A | No | No | 0 | 16,892 | 0.00 | 510,094 |
31 Jan 24 | Lucido Louis C. | Common Stock, par value $0.001 | Grant | Acquire A | No | No | 0 | 18,269 | 0.00 | 493,202 |
16 Jan 24 | Lucido Louis C. | Common Stock, par value $0.001 | Buy | Acquire P | No | No | 0.7 | 126 | 88.20 | 474,933 |
12 Jan 24 | Lucido Louis C. | Common Stock, par value $0.001 | Buy | Acquire P | No | No | 0.7 | 3,000 | 2.10 k | 474,807 |
Press releases
BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia
3 Apr 24
BioCorRx Reports Business Update for 2023
2 Apr 24
BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD
28 Feb 24
BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors
8 Feb 24